CMS Open Payments · Program Year 2024
Kuraray America Inc.
Kuraray America Inc. reported $352,262.23 across General Payments, Research, and Ownership to 611 physicians and teaching hospitals across 611 transactions.
- $352.3K Above-median payer
- All-tracks total
- 611 Above-median volume
- Transactions
- 611 Above-median reach
- Recipients
- −$81.4K
- General Payments vs PY2023
Kuraray America Inc. reported $352,262.23 across all CMS Open Payments tracks (General + Research + Ownership) to 611 physicians and teaching hospitals in Program Year 2024 - ranking #858 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $352,262.23, averaging $576.53 per recipient.
How Kuraray America Inc.'s $352.3K all-tracks total breaks down
Kuraray America Inc.'s payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
33/100
Total payments
F
13/100
Transaction volume
F
14/100
Physician reach
F
15/100
Payment type diversity
A
90/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer kuraray-america-inc Kuraray America Inc.
$352.3K · #858/1,925 · 0.0% industry · PY2024
- TOT $352.3K
- RANK #858
- SHARE 0.0%
- TXN 611
- RCP 611
- CAT 7
- GEN $352.3K
- ΔGEN −$81.4K
- TOP1 19.3%
- PY 2024
Volume peers
Nearest volume peer: Biogennix, LLC ($352.9K)
Kuraray America Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Kuraray America Inc.'s CMS-reported General Payments decreased by $81.4K (−18.8%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: KURARAY AMERICA INC.PY2023: KURARAY AMERICA INC.PY2024: Kuraray America Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $433,673.73
- PY2024
- $352,262.23
What the Data Shows for Kuraray America Inc.
The all-tracks total above combines three CMS reporting categories - General Payments, Research Payments, and Ownership/Investment interests - not one undifferentiated figure. For Kuraray America Inc., that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS publishes each Program Year's data roughly 12 months after the reporting period ends, so this reflects the most recently released cycle; see our methodology for how the tracks are standardized and compared across companies.
"Honoraria" leads the 7-category general-payment breakdown below at $212.3K (60.3% of General Payments, 59 transactions) - see our methodology for how research and ownership payments are reported separately.
General Payment Breakdown by Type
"Honoraria" leads Kuraray America Inc.'s 7-category general-payment breakdown at $212.3K, 60.3% of the reported total.
Kuraray America Inc. reports 7 general-payment categories - the top three are Honoraria (60.3%), Travel and Lodging (23.9%), and Food and Beverage (8.2%). The remaining 4 categories make up 7.6% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How Kuraray America Inc. divides its payments
Ranked by total dollars reported per category
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Honoraria | $212.3K | 59 | 60.3% |
| Travel and Lodging | $84.4K | 173 | 23.9% |
| Food and Beverage | $28.8K | 362 | 8.2% |
| Consulting Fee | $24.0K | 1 | 6.8% |
| Education | $2.7K | 13 | 0.8% |
| Entertainment | $103.99 | 2 | 0.0% |
| Gift | $22.14 | 1 | 0.0% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $173,708.51 (49.3%) of $352,262.23 in this company's General Payments records across 326 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Kuraray America Inc.
The five named recipients with the highest reported General Payments from this company
- 1
ROBERT Gregory CAMPBELL
$67,985.66 across 30 reported transactions
- 2
Jeffrey Hoos
$40,800.00 across 5 reported transactions
- 3
Troy Schmedding
$31,629.84 across 15 reported transactions
- 4
Richard Young
$17,053.99 across 14 reported transactions
- 5
Amelia Orta
$16,239.02 across 7 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Kuraray America Inc. ranks #858 of 1,925 by total payments (top 45% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #1,175 of 1,838 by HHI (bottom 36% least concentrated), a wider distribution than most similarly sized payers.
View all 12 companies in this HHI neighborhood as a list
- Nordic Pharma, Inc. : $142.6K total payments, HHI 700
- Neurent Medical Limited : $525.6K total payments, HHI 699
- Medexus Pharma, Inc. : $75.6K total payments, HHI 698
- BK Medical Holding Company Inc. : $164.8K total payments, HHI 693
- HEMA Biologics, LLC : $276.5K total payments, HHI 691
- Precision Spine, Inc. : $802.9K total payments, HHI 690
- Kuraray America Inc. (this company) : $352.3K total payments, HHI 690
- Ascendis Pharma Inc : $470.4K total payments, HHI 686
- Distalmotion US : $620.2K total payments, HHI 685
- Maxx Orthopedics, Inc. : $96.6K total payments, HHI 683
- Janssen Scientific Affairs, LLC : $5.7M total payments, HHI 681
- Dentsply Sirona Inc : $10.4M total payments, HHI 679
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Kuraray America Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Kuraray America Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Kuraray America Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
elliquence, LLC
UCB GmbH
SOMAVAC Medical Solutions, Inc.
Bernhard Foerster GmbH
Genmab BV
Put this to use
Kuraray America Inc. ranks #858 of 1,925 by all-tracks total payments, led by "Honoraria".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Honoraria" spend across every manufacturer, not just Kuraray America Inc.. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.